396 related articles for article (PubMed ID: 36457998)
1. Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.
Xia Y; Wang D; Piao Y; Chen M; Wang D; Jiang Z; Liu B
Front Immunol; 2022; 13():1025532. PubMed ID: 36457998
[TBL] [Abstract][Full Text] [Related]
2. Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.
Chen H; Gong Z; Zhou H; Han Y
Drug Dev Res; 2024 Apr; 85(2):e22167. PubMed ID: 38444106
[TBL] [Abstract][Full Text] [Related]
3. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.
Tan J; Feng X; Wu H; Yang B; Shi M; Xie C; Su Z; Li L; Luo M; Zuo Z; Zhu S; Yang J; Lin L
J Immunol Res; 2022; 2022():6568278. PubMed ID: 36065454
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine (m6A) modification in osteosarcoma: expression, function and interaction with noncoding RNAs - an updated review.
Zhang Y; Xu Y; Bao Y; Luo Y; Qiu G; He M; Lu J; Xu J; Chen B; Wang Y
Epigenetics; 2023 Dec; 18(1):2260213. PubMed ID: 37766615
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of immunogenic cell death indicates prognosis and tumor microenvironment infiltration in osteosarcoma.
Liu Z; Liu B; Feng C; Li C; Wang H; Zhang H; Liu P; Li Z; He S; Tu C
Front Immunol; 2022; 13():1071636. PubMed ID: 36569869
[TBL] [Abstract][Full Text] [Related]
7. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
Yu L; Zhang J; Li Y
Front Immunol; 2022; 13():871076. PubMed ID: 36311748
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress.
Cheng S; Wang H; Kang X; Zhang H
Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399305
[TBL] [Abstract][Full Text] [Related]
9. The role of non‑coding RNAs in the regulation, diagnosis, prognosis and treatment of osteosarcoma (Review).
Yang G; Wu Y; Wan R; Sang H; Liu H; Huang W
Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34296296
[TBL] [Abstract][Full Text] [Related]
10. Treating osteosarcoma with CAR T cells.
Köksal H; Müller E; Inderberg EM; Bruland Ø; Wälchli S
Scand J Immunol; 2019 Mar; 89(3):e12741. PubMed ID: 30549299
[TBL] [Abstract][Full Text] [Related]
11. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
12. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment phenotypes and prognostic evaluation tools for osteosarcoma characterized by different prognostic outcomes and immunotherapy responses.
Tu Z; Li W; Chen Z; Jiang D; Zhou S; Lv S; Cui H
J Gene Med; 2024 Jan; 26(1):e3572. PubMed ID: 37525871
[TBL] [Abstract][Full Text] [Related]
14. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
16. Necrotizing apoptosis-related genes prognosis and treatment effect analysis of osteosarcoma in children.
Chen Y; Wu L; Li Y; Zheng J; Zhong S; Gu S; Chen J
J Gene Med; 2024 Jan; 26(1):e3646. PubMed ID: 38100138
[TBL] [Abstract][Full Text] [Related]
17. N6-Methyladenosine-Related LncRNAs Are Potential Remodeling Indicators in the Tumor Microenvironment and Prognostic Markers in Osteosarcoma.
Wu Z; Zhang X; Chen D; Li Z; Wu X; Wang J; Deng Y
Front Immunol; 2021; 12():806189. PubMed ID: 35095893
[TBL] [Abstract][Full Text] [Related]
18. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
Mensali N; Köksal H; Joaquina S; Wernhoff P; Casey NP; Romecin P; Panisello C; Rodriguez R; Vimeux L; Juzeniene A; Myhre MR; Fåne A; Ramírez CC; Maggadottir SM; Duru AD; Georgoudaki AM; Grad I; Maturana AD; Gaudernack G; Kvalheim G; Carcaboso AM; de Alava E; Donnadieu E; Bruland ØS; Menendez P; Inderberg EM; Wälchli S
Nat Commun; 2023 Jun; 14(1):3375. PubMed ID: 37291203
[TBL] [Abstract][Full Text] [Related]
19. Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.
Wang C; Jing J; Cheng L
Invest New Drugs; 2018 Dec; 36(6):1116-1132. PubMed ID: 30079443
[TBL] [Abstract][Full Text] [Related]
20. Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy.
Jin Z; Sun X; Wang Y; Zhou C; Yang H; Zhou S
Front Immunol; 2022; 13():1018903. PubMed ID: 36300110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
